Leukocyte apheresis
A medical device therapy known as leukocyte apheresis (selective granulocyte/monocyte adsorptive {GMA} apheresis; GMDN[1] code: 47306) works by removing from the blood a group of white blood cells called activated leukocytes[2] which play a key role in the inflammatory stages of ulcerative colitis (UC)[3]. Selectively reducing these cells in the blood helps to reduce inflammation in the colon[4]. Leukocyte apheresis can help UC patients with chronic, grumbling disease who are either unsuitable for, intolerant of, or failing on medicines described above[5].
- ^ "Global Medical Device Network".
- ^ Hanai H.; et al. (January 2011). "The mode of actions of the Adacolumn therapeutic leucocytapheresis in patients with inflammatory bowel disease: a concise review". Clinical & Experimental Immunology (163(1) ed.): 50–58.
{{cite journal}}: Explicit use of et al. in:|last=(help) - ^ Nikolaus S., Schreiber S.; et al. (April 1998). "Increased secretion of pro-inflammatory cytokines by circulating polymorphonuclear neutrophils and regulation by interleukin 10 during intestinal inflammation". Gut (42(4) ed.): 470–476.
{{cite journal}}: Explicit use of et al. in:|last=(help) - ^ Muratov V.; et al. (2008). "Decreased numbers of FoxP3-positive and TLR-2-positive cells in intestinal mucosa are associated with improvement in patients with active inflammatory bowel disease following selective leukocyte apheresis". Journal of Gastroenterology (43): 277-282.
{{cite journal}}: Explicit use of et al. in:|last=(help) - ^ Dignass A.; et al. (2015). "P511 Efficacy and safety of granulocyte/monocyte adsorptive apheresis in steroid-dependent Active Ulcerative Colitis with insufficient response or intolerance to immunosuppressants and/or biological therapies (the ART trial): Results at 24 and 48 weeks". ecco-ibd.eu. The European Crohn's and Colitis Organisation (ECCO).
{{cite web}}: Explicit use of et al. in:|last=(help)